Price Chart

Profile

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
URL https://www.legendbiotech.com
Investor Relations URL https://investors.legendbiotech.com/
HQ State/Province New Jersey
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release Mar. 11, 2025 (est.)
Last Earnings Release Nov. 12, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
URL https://www.legendbiotech.com
Investor Relations URL https://investors.legendbiotech.com/
HQ State/Province New Jersey
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release Mar. 11, 2025 (est.)
Last Earnings Release Nov. 12, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A